Advantages and Challenges of Platform Trials for Disease Modifying Therapies in Parkinson's Disease
Movement Disorders · 2024-09 · 39 (9) · 1468-1477
DOI: 10.1002/mds.29899 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Movement Disorders, online erschienen am 26.06.2024. Verfasst von Margherita Fabbri und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology and Neurosciences, Clinical Investigation Center CIC1436, Toulouse Parkinson Expert Center, Toulouse NeuroToul Ce…. Hauptthemen laut MEDLINE: Parkinson Disease, Clinical Trials as Topic. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 50 Literaturangaben.
Abstract (Originalsprache)
Traditional drug development in Parkinson's disease (PD) faces significant challenges because of its protracted timeline and high costs. In response, innovative master protocols are emerging and designed to address multiple research questions within a single overarching protocol. These trials may offer advantages such as increased efficiency, agility in adding new treatment arms, and potential cost savings. However, they also present organizational, methodological, funding, regulatory, and sponsorship challenges. We review the potential of master protocols, focusing on platform trials, for disease modifying therapies in PD. These trials share a common control group and allow for the termination or addition of treatment arms during a trial with non‐predetermined end. Specific issues exist for a platform trial in the PD field considering the heterogeneity of patients in terms of phenotype, genotype and staging, the confounding effects of symptomatic treatments, and the choice of outcome measures with no consensus on a non‐clinical biomarker to serve as a surrogate and the slowness of PD progression. We illustrate these aspects using the examples of the main PD platform trials currently in development with each one targeting distinct goals, populations, and outcomes. Overall, platform trials hold promise in expediting the evaluation of potential therapies for PD. However, it remains to be proven whether these theoretical benefits will translate into increased production of high‐quality trial data. Success also depends on the willingness of pharmaceutical companies to engage in such trials and whether this approach will ultimately hasten the identification and licensing of effective disease‐modifying drugs. © 2024 International Parkinson and Movement Disorder Society.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology and Neurosciences, Clinical Investigation Center CIC1436, Toulouse Parkinson Expert Center, Toulouse NeuroToul Center of Excellence in Neurodegeneration (COEN), French NS-Park/F-CRIN…
- Department of Clinical and Movement Neurosciences, UCL Institute of Neurology, London, United Kingdom.
- Translational and Clinical Research Institute, Newcastle University, Newcastle, United Kingdom.
- Department of Neurology and Neurosurgery, McGill University, Montreal Neurological Institute, Montreal, Quebec, Canada.
- Université Paris Cité and Université Sorbonne Paris Nord, INSERM, INRAE, Center for Research in Epidemiology and StatisticS (CRESS), Paris, France.
- Center for Clinical Epidemiology, Assistance Publique-Hôpitaux de Paris, Hôtel-Dieu Hospital, Paris, France.
ORCID-Profile: Margherita Fabbri, Olivier Rascol, Tom Foltynie, Ronald B Postuma
Zitieren
APA
Fabbri, M., Rascol, O., Foltynie, T., Carroll, C., Postuma, R. B., Porcher, R., & Corvol, J. C. (2024). Advantages and Challenges of Platform Trials for Disease Modifying Therapies in Parkinson's Disease. Movement Disorders, 39(9), 1468-1477. https://doi.org/10.1002/mds.29899
Vancouver
Fabbri M, Rascol O, Foltynie T, Carroll C, Postuma RB, Porcher R, et al. Advantages and Challenges of Platform Trials for Disease Modifying Therapies in Parkinson's Disease. Movement Disorders. 2024;39(9):1468-1477. doi:10.1002/mds.29899
BibTeX
@article{Fabbri2024,
author = {Fabbri, Margherita and Rascol, Olivier and Foltynie, Tom and Carroll, Camille and Postuma, Ronald B and Porcher, Raphael and Corvol, Jean Christophe},
title = {Advantages and Challenges of Platform Trials for Disease Modifying Therapies in Parkinson's Disease},
journal = {Movement Disorders},
year = {2024},
volume = {39},
number = {9},
pages = {1468--1477},
doi = {10.1002/mds.29899}
}
EUVIMED